Clinical trials: Mental
Bipolar Disorder, Major Depressive Disorder
Clinical Validation Study for EDIT-B Test: an Aid for Differential Diagnosis of Bipolar Disorder, Based on RNA Editing Blood Biomarkers
Differentiation between major depressive disorder (MDD) and bipolar disorder (BD) as soon as possible in the patient journey represents a major clinical issue.
- Trial name
- EDIT-B (NCT05603819)
- Testing
- EDIT-B
- Where
- 4 sites in Denmark, France and 1 more
- Volunteers
- 418 people
- Sponsor
- Alcediag
Schizophrenia
Assessment of Schizophrenia Patients' Clinical Study Experiences
The study seeks to delve into the firsthand experiences of patients diagnosed with schizophrenia who partake in a separate clinical trial featuring a specific medical intervention.
- Trial name
- NCT05948111
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Schizophrenia
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
This study will be conducted to evaluate the efficacy, safety, and tolerability of GWP42003-P versus placebo in participants with schizophrenia experiencing inadequate response to ongoing antipsychotic treatment.
- Trial name
- NCT04421456
- Testing
- GWP42003-P
- Where
- 39 sites in United States, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Jazz Pharmaceuticals
Premature Ejaculation
Study to Evaluate Efficacy and Safety in Males Subjects With Premature Ejaculation
The purpose of this clinical trial is to test an experimental drug therapy called Tramadol Hydrochloride (HCl) Orally Disintegrating Tablets (ODT) ("Tramadol HCl ODT" or the "study drug").
- Trial name
- NCT00983151
- Where
- 38 sites in Austria, Belgium and 5 more
- Volunteers
- 1,050 people
- Sponsor
- Bausch Health Americas, Inc.
Insomnia
A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia
The primary objective of the study is to evaluate the proportion of adult [greater than or equal to (>=) 18 years] participants with insomnia disorder taking zolpidem tartrate immediate release (ZOL-IR) or zolpidem tartrate…
- Trial name
- NCT04009577
- Testing
- LEM 5 mg, LEM 10 mg
- Where
- 17 sites in United States
- Volunteers
- 53 people
- Sponsor
- Eisai Inc.
Bipolar Depression
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
The primary objective of this study is to evaluate the superior efficacy of quetiapine extended release(XR) mono-therapy, administered once daily compared to placebo, in the treatment of depressive symptoms in patients with…
- Trial name
- NCT01256177
- Testing
- Quetiapine Fumarate (SEROQUEL) Extended Release
- Where
- 12 sites in China
- Volunteers
- 361 people
- Sponsor
- AstraZeneca
Alzheimer's Disease, Dementia
A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease
The purpose of this study is to demonstrate the safety and efficacy of PF-01913539 in the treatment of patients with mild-to-moderate Alzheimer's Disease.
- Conditions
- Alzheimer's Disease, Dementia, Dimebon, Investigational Drug
- Trial name
- NCT01066481
- Testing
- PF-01913539 5 mg
- Sponsor
- Pfizer
Adult Attention Deficit Hyperactivity Disorder
Researching the Effectiveness of Attexis, a Digital Health Application for Adults With Attention Deficit Hyperactivity Disorder
In this randomized controlled clinical trial, 326 patients with ADHD will be investigated regarding the effectiveness of a digital therapeutic for improved ADHD symptomatology, the unguided online intervention attexis.
- Trial name
- READ-ADHD (NCT06221930)
- Testing
- attexis
- Where
- Germany
- Volunteers
- 337 people
- Sponsor
- Gaia AG
Huntington's Disease
A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease
The primary purpose of this study is to assess the effect of food upon the pharmacokinetics (PK) of SEN0014196 in subjects with Huntington disease (HD).
- Trial name
- NCT01485965
- Testing
- SEN0014196
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Siena Biotech S.p.A.
Alzheimer's Disease, Healthy Participants
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration
The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with…
- Trial name
- NCT07780383
- Testing
- BMS-986446
- Where
- 6 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Erectile Dysfunction Due to Arterial Insufficiency
Incidence of Male Pudendal Artery Stenosis in Suboptimal Erections Study
The purpose of this study is to determine the proportion of men with known or suspected coronary artery disease (CAD) and/or peripheral arterial disease (PAD) that have angiographic identifiable erectile related artery (ERA)…
- Trial name
- IMPASSE (NCT01341483)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Medtronic Endovascular
Bipolar Disorder
The Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania
The purpose of this study is to evaluate effect of risperidone as a long-term combination therapy to mood stabilizers in the treatment of bipolar mania
- Trial name
- NCT00216554
- Testing
- risperidone
- Volunteers
- 118 people
- Sponsor
- Janssen Korea, Ltd., Korea
Bipolar Disorder
Bioequivalency Study of 300 mg Lithium Carbonate Under Fed Conditions
The objective of this study was the bioequivalence of a Roxane lithium carbonate 300 mg extended release tablet formulation compared to Solvay's Lithobid 300 mg extended release tablet under fed conditions using a single-dose…
- Trial name
- NCT00602394
- Testing
- Lithium
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Work Related Stress, Sense of Coherence
An Evaluation Study to Identify the Effectiveness of Clinical Supervision With Regards to Work-related Strain, Sense of Coherence, Increased Cultural Sensitivity and the Impact on Patient's Care: A Prospective Longitudinal Study in Mental Health Services in Qatar
Clinical supervision (CS) is a pragmatic approach, which enables nurses to work together; it can create a positive nursing environment, reduce stress, and increase clinical skills through peer support.
- Conditions
- Work Related Stress, Sense of Coherence, Cultural Sensitivity, Clinical Supervision
- Trial name
- NCT04196751
- Testing
- Clinical Supervision
- Where
- Qatar
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Alzheimer's Dementia
Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia
This phase IIIb study is intended to implement a consistent treatment way for switching to Exelon transdermal patch from oral formulation of rivastigmine to stress the importance of (1) advantages of transdermal patch over…
- Trial name
- NCT01585272
- Testing
- ENA713
- Where
- 4 sites in Taiwan
- Volunteers
- 121 people
- Sponsor
- Novartis Pharmaceuticals
Depression Disorders, Anxiety Disorders
Expansion and Evaluation of AI-generated Clinical Assessment (AI-COA®) of Depression and Anxiety Severity
The SEQUOIA-1 study evaluates the effectiveness of Artificial Intelligence (AI) in measuring depression and anxiety severity in adults. Investigators from Deliberate Solutions, Inc.
- Trial name
- SEQUOIA-1 (NCT06923995)
- Testing
- AI-driven clinical interview
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Deliberate Solutions Inc.
Depressive Disorder, Major
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive…
- Trial name
- Moonlight-1 (NCT06785012)
- Testing
- JNJ-89495120
- Where
- 44 sites in United States
- Volunteers
- 105 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00208156
- Testing
- Mifepristone
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- Corcept Therapeutics
Alcohol Dependence
ALK33-001: A Study of RDC-0313 Administered to Healthy Adults
The purpose of this study is to determine the pharmacokinetics, safety, and tolerability of RDC-0313 following oral administration.
- Trial name
- NCT00800319
- Testing
- RDC-0313
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Narcolepsy With Cataplexy
Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes
To monitor for endocrine changes in response to treatment of cataplexy with Xyrem, to focus on the hypothalamic pituitary axis and to confirm the safety of Xyrem on potential endocrine changes.
- Trial name
- NCT00345800
- Testing
- Sodium Oxybate (Xyrem)
- Where
- Belgium
- Volunteers
- 25 people
- Sponsor
- UCB Pharma SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.